QuatRx Anticipates NDA Filing For Vaginal Atrophy Therapy Ophena In 2009/2010
This article was originally published in The Pink Sheet Daily
Executive Summary
The non-estrogen treatment for postmenopausal women is a potential blockbuster, CEO Zerbe tells “The Pink Sheet” DAILY.
You may also be interested in...
Shionogi Builds Women's Health And Sexual Health Portfolio With QuatRx Deal
The U.S. subsidiary of Shionogi acquired global development and marketing rights to QuatRx Pharmaceuticals' selective estrogen receptor modulator ospemifene, building on the company's sexual medicine and women's health portfolio
Shionogi Builds Women's Health And Sexual Health Portfolio With QuatRx Deal
Shionogi Pharma will pay $25 million upfront and up to $100 million in milestone payments for selective estrogen receptor modulator ospemifene, which it expects to file in the second half for the treatment of postmenopausal vulvovaginal atrophy.
Shionogi Builds Women's Health And Sexual Health Portfolio With QuatRx Deal
Shionogi Pharma will pay $25 million upfront and up to $100 million in milestone payments for selective estrogen receptor modulator ospemifene, which it expects to file in the second half for the treatment of postmenopausal vulvovaginal atrophy.